Exscientia takes full ownership of cdk7 inhibitor in oncology breakthrough
Exscientia plc (Nasdaq: EXAI), a pioneer in AI-driven drug discovery, has reached a strategic milestone by acquiring full ownership of the oral CDK7 inhibitor program from GT Apeiron, taking control of the promising compound GTAEXS617 (‘617) along with all associated intellectual property. Under the terms of the agreement, Exscientia will pay GT Apeiron $10 million […]